ARTICLE | Strategy
InSite's new vision
InSite Vision resized, refunded, refocusing on late-stage ophthalmology pipeline
August 15, 2011 7:00 AM UTC
InSite Vision Inc. thought it was poised for success in 2007 when, after 20 years of effort and more than $52 million raised from investors, the company's first drug, AzaSite 1% azithromycin ophthalmic solution, was approved by FDA for bacterial conjunctivitis (pink eye).
Instead, according to CEO Timothy Ruane, an ill-considered partnership and poor commercial planning got the company into trouble...